Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikayce) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.

Next Previous
X
Search
Trial Profile

Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikayce) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Transave

    • Most Recent Events

    • 04 May 2012 Company (Insmed) added to the associations field as reported by ClinicalTrials.gov.
    • 04 May 2012 Actual patient number is 46 according to ClinicalTrials.gov.
    • 19 May 2010 Results presented at the 106th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top